Dinesh V Ph D. Patel - 10 Aug 2026 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Reporting relationship: President and CEO, Director
Issuer ticker: PTGX
Reported as of: 10 Aug 2026
Net transaction value: -$14,890,799
SEC form: 4
Accepted by SEC: 12 Aug 2026, 18:43:08 UTC
Prior SEC filing: 14 May 2026
Next SEC filing: 08 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.

Key filing fact

Dinesh V Ph D. Patel filed Form 4 for Protagonist Therapeutics, Inc (PTGX) on 12 Aug 2026.

Key facts

This page summarizes Dinesh V Ph D. Patel's Form 4 filing for Protagonist Therapeutics, Inc (PTGX).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Aug 2026, 18:43.

Change

Previous filing in this sequence was filed on 14 May 2026.
Current net transaction value: -$14,890,799.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001120477 Primary reporting owner

PATEL DINESH V PH D

Relationship: President and CEO, Director
Address: C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +65,761
Change %: +13%
Price: $21.58^*
Shares after: 589,239
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Sale

Transaction value: $9,805,623
Shares: -65,761
Change %: -11%
Price: $149.11
Shares after: 523,478
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F2

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +34,239
Change %: +6.5%
Price: $21.58^*
Shares after: 557,717
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Sale

Transaction value: $5,085,176
Shares: -34,239
Change %: -6.1%
Price: $148.52
Shares after: 523,478
Date: 11 Aug 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -65,761
Change %: -29%
Price: $0.000000^*
Shares after: 159,239
Date: 10 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,761
Exercise price: $21.58
Footnotes: F1

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -34,239
Change %: -22%
Price: $0.000000^*
Shares after: 125,000
Date: 11 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 34,239
Exercise price: $21.58
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.

Footnote F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.